American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023
Treatment-experienced patient with Roux-en-Y gastric bypass successfully treated with sofosbuvir/velpatasvir/voxilaprevir: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mod Alexis Taylor, Katz Rivka
Аннотация
PURPOSE: The purpose of this article is to describe a patient with chronic hepatitis C virus (HCV) infection, who had previously taken 2 other direct-acting antiviral (DAA) regimens and undergone Roux-en-Y gastric bypass (RYGB), successfully treated with a sofosbuvir/velpatasvir/voxilaprevir regimen.
SUMMARY: A 64-year-old, African American male presented for management of HCV genotype 1a infection after 2 failed courses of treatment. The patient had a history of severe gastroesophageal reflux disease (GERD), and he was unable to discontinue proton pump inhibitor (PPI) use during all treatment regimens. He was originally treated with 12 weeks of ledipasvir/sofosbuvir but relapsed 3 to 4 months post treatment. The patient had undergone RYGB for the treatment of obesity. After surgery, the patient was re-treated with sofosbuvir/velpatasvir plus ribavirin for 24 weeks. The patient again relapsed 3 months after completing therapy. At our clinic, the patient was started on sofosbuvir/velpatasvir/voxilaprevir for 12 weeks. The patient decided on his own to chew the medication, as he was concerned about medication absorption post surgery, and took concurrent once-daily esomeprazole. Confirmatory posttreatment laboratory work showed his HCV RNA viral load remained undetectable, indicating sustained virologic response, and the patient was deemed cured of HCV.
CONCLUSION: A patient with a history of relapse after previous DAA therapy and RYGB was successfully treated for HCV infection with sofosbuvir/velpatasvir/voxilaprevir tablets, which he chewed. This case report shows sofosbuvir/velpatasvir/voxilaprevir may be an effective treatment option in the RYGB population, although additional research is needed.
SUMMARY: A 64-year-old, African American male presented for management of HCV genotype 1a infection after 2 failed courses of treatment. The patient had a history of severe gastroesophageal reflux disease (GERD), and he was unable to discontinue proton pump inhibitor (PPI) use during all treatment regimens. He was originally treated with 12 weeks of ledipasvir/sofosbuvir but relapsed 3 to 4 months post treatment. The patient had undergone RYGB for the treatment of obesity. After surgery, the patient was re-treated with sofosbuvir/velpatasvir plus ribavirin for 24 weeks. The patient again relapsed 3 months after completing therapy. At our clinic, the patient was started on sofosbuvir/velpatasvir/voxilaprevir for 12 weeks. The patient decided on his own to chew the medication, as he was concerned about medication absorption post surgery, and took concurrent once-daily esomeprazole. Confirmatory posttreatment laboratory work showed his HCV RNA viral load remained undetectable, indicating sustained virologic response, and the patient was deemed cured of HCV.
CONCLUSION: A patient with a history of relapse after previous DAA therapy and RYGB was successfully treated for HCV infection with sofosbuvir/velpatasvir/voxilaprevir tablets, which he chewed. This case report shows sofosbuvir/velpatasvir/voxilaprevir may be an effective treatment option in the RYGB population, although additional research is needed.